AI Analysis
AI-generated analysis. Always verify with the original filing.
Operating Income was -$110.1M (-8.1%) Net Income was -$96.2M (-8.3%) Eps was $-1.03 (8.0%) Free Cash Flow was -$82.2M
Key Takeaways
1Operating loss widened to $110.1M (vs. $101.9M in FY2024), reflecting accelerated investment in TERN-701’s CARDINAL trial and preparation for Phase 3 initiation in late 2026.
2Diluted EPS improved to $-1.03 (from $-1.12), not due to profitability but because share count increased less than net loss — reflecting disciplined capital efficiency despite large raises.
3Net cash used in operating activities was $82.2M, driven by research and development spending, consistent with a clinical-stage biotech advancing its lead oncology asset.
4Free cash flow equaled $-82.2M, as capital expenditures were negligible, underscoring the asset-light nature of late-stage drug development at this phase.
5Interest income trends reflect higher average balances of cash and marketable securities, resulting from recent equity financings that expanded the company's financial runway.